Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alfacell says Onconase shows preclinical promise
The research demonstrated that Onconase significantly inhibited tumor growth by inducing apoptosis (cell death) in human non-small cell lung cancer (NSCLC) cells and human breast cancer cells without
The research demonstrated that Onconase significantly inhibited tumor growth by inducing apoptosis (cell death) in human non-small cell lung cancer (NSCLC) cells and human breast cancer cells without
Results of the studies demonstrated a potent, dose-dependent inhibition of tumor growth following the administration of the compound ENMD-1420 in two distinct preclinical models of metastatic lung and
Telaprevir was evaluated in combination with pegylated interferon and ribavirin in treatment-naive, genotype 1-infected hepatitis C patients. In the study, 88% and 79% of patients receiving telaprevir achieved
The company received European Union marketing authorization for Thelin in August 2006. Thelin is the first selective endothelin A receptor antagonist and the first once-daily oral treatment available
ThromboGenics said it is outlicensing its stem cell research platform as part of a strategic plan to invest resources in its preclinical pipeline. Revenue derived from this license
GPC Biotech is requesting the approval of satraplatin as a treatment in combination with prednisone for patients with hormone-refractory prostate cancer whose prior chemotherapy has failed. Priority review
The new dose will treat specific patient populations, including those with renal and hepatic impairment. Risperdal Consta is manufactured by Alkermes and marketed in the US by Janssen.
These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with Baraclude also achieved liver enzyme (ALT) normalization.
This trial follows positive results from a phase I trial of the gene therapy CERE-120 in 12 patients in which preliminary data showed the treatment to be well
SkyePharma said Requip extended release has been designed to provide a steady rate of absorption in the body to help reduce blood plasma fluctuations over 24 hours. The